English  丨  中文
English  丨  中文
About Us

The founders and executives of Sirnaomics, Inc. bring valuable expertise from the biopharmaceutical industry as well as finance and business management.

Patrick Y. Lu, Ph.D, Founder, President and CEO of Sirnaomics, Inc., and Chairman of Board of Directors, Suzhou Sirnaomics Pharmaceuticals, Ltd., in Biobay, SIP, China.  He also serves as a "1000 Talents" Expert, and Adjunct Professor of Nanjing University and South China University of Technology. Dr. Lu started his biopharmaceutical industry career in 1993 and served as a lab head and senior scientist in Novartis and Digene (until 2000). Dr. Lu was the co-founder and Executive Vice President of Intradigm Corporation (2001-2006). Patrick has authored more than 50 scientific papers, review articles and book chapters, and holds 35 issued and pending international patents. He has been an invited speaker in many international conferences throughout the world. Dr. Lu has been awarded a number of grants from NIH, the State and County governments. 

Michael Molyneaux, MD, MBA, Chief Medical OfficerBefore joining the company, Dr. Molyneaux served as CMO of Marcrosure Ltd. (NASDAQ: MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds. He was a member of Management leadership team that participated in the IPO in 2014 and raised 55 million dollars. He completed his medical school and residency training at Dalhousie University in Nova Scotia, Canada and is board certified in both Canada and the United States. He also completed an MBA at Washington University in St. Louis, and a BSc, Biology at University Prince Edward Island in Prince Edward Island, Canada.


Marc M. Lemaître, Ph.D, Chief Operation Officerhas 30 years of pioneering experience in oligonucleotide development and manufacturing and is the former CEO of Girindus America Inc. and Vorstand of Girindus AG. After pioneering work on Antisense and oligonucleotide delivery in Montpellier, France with Lebleu and Imbach's groups, followed by 2 years in the lab of Nobel Prize winner Dr. Luc Montagnier at the Pasteur Institute in Paris, He moved to the USA in 2006 in a leadership role with Glen Research, before being recruited in 2009 as CEO of Girindus America, a CMO with a focus on the cGMP manufacture of oligonucleotides for therapeutic applications. In this role, Marc also held the legal responsibility of "Sprecher des Vorstands" (President of the management board) of the German listed company Girindus AG, adding invaluable experience of leadership of a public company. Having negotiated the merger between Nitto-Denko Avecia and the US operations of Girindus, working as an independent consultant and joined the Sirnaomics team in 2014.


David M. Evans, Ph.D, Co-founder.  Dr. Evans has over 20 years experience in drug target and small molecule discovery for oncology, infectious diseases and CNS therapeutics. Dr. Evans has been a pioneer in target/drug discovery technologies including high throughput gene silencing using RNAi.  Before joining Sirnaomics, Inc. David served as Sr. Director, RNAi Discovery and Therapeutic Services group, Thermo Fisher Scientific (TFS), Lafayette, CO; Head of Drug Discovery, Cancer Drug Development Lab Translational Genomics Research Institute (TGEN), Gaithersburg, MD; Director, Drug Discovery Psychiatric Genomics Inc., Gaithersburg, MD; and Head, High Throughput Screening for Serono Pharmaceuticals, Boston, MA. Prior to this David was with Millennium Pharmaceuticals, Cambridge, MA. Dr. Evans is the inventor on a number of issued and pending patents, and has been an invited speaker for many international professional conferences and webinars on siRNA screening and drug discovery. He received his BSc (1983) and PhD (1987) from Imperial College, London and has published a number of peer reviewed papers and review articles.

George Ji, MBA, Co-founder,  Senior Vice President, Corporate Development. George formally served as Managing Director of China Biopharma, Inc., a U.S. listed biopharmaceutical company head-quartered in New Jersey. In this role George was responsible for oversight of corporate affairs supervising U.S. operations and corporate development of this public company. Prior to this position, George was Director of Business Development at Quantum Communications (New Jersey), where he led the planning and development of new business and was directly involved in service design and support for both U.S. and international markets. Mr. Ji has also held several business development and managerial positions in other U.S. and international firms including GE and ASME. Mr. Ji obtained a Fulbright M.A. in American Studies (1987), and holds an MBA degree from Webster University (1998).

Alan Y. Lu, Ph.D, MBA, Executive Vice President for Product Development. Dr. Lu has significant experience in both academic and industrial settings focused on vaccine and therapeutic development. Prior to joining Sirnaomics, he served as the VP for Research and Business Development, Synaptic Research and as a Research Associate with a faculty appointment at the Department of Neurology, Johns Hopkins University School of Medicine. Dr. Lu received his Ph.D. from Univ. of Illinois (UIUC), Urbana, Illinois and postdoctoral training from NIH and UIUC. Dr. Lu also received his MBA from The Johns Hopkins Carey Business School.

Alan Y. Lu, Ph.D, MBA, Executive Vice President for Product Development. Dr. Lu has significant experience in both academic and industrial settings focused on vaccine and therapeutic development. Prior to joining Sirnaomics, he served as the VP for Research and Business Development, Synaptic Research and as a Research Associate with a faculty appointment at the Department of Neurology, Johns Hopkins University School of Medicine. Dr. Lu received his Ph.D. from Univ. of Illinois (UIUC), Urbana, Illinois and postdoctoral training from NIH and UIUC. Dr. Lu also received his MBA from The Johns Hopkins Carey Business School.